Cargando…
La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad
Injuries caused by venomous animals affect vast areas of Latin America, Southern Asia, Southeast Asia, sub-Saharan Africa, and Oceania, and pose a serious problem for global public health. Based on an analysis of the current panorama of global production of ophidian and arachnid antivenoms, it is co...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Organización Panamericana de la Salud
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645312/ https://www.ncbi.nlm.nih.gov/pubmed/28902267 http://dx.doi.org/10.26633/RPSP.2017.109 |
_version_ | 1783437437296443392 |
---|---|
author | Temprano, Guillermo Aprea, Patricia Christian Dokmetjian, José |
author_facet | Temprano, Guillermo Aprea, Patricia Christian Dokmetjian, José |
author_sort | Temprano, Guillermo |
collection | PubMed |
description | Injuries caused by venomous animals affect vast areas of Latin America, Southern Asia, Southeast Asia, sub-Saharan Africa, and Oceania, and pose a serious problem for global public health. Based on an analysis of the current panorama of global production of ophidian and arachnid antivenoms, it is concluded that they are semi-orphaned products. This is a favorable scenario in which to strengthen public laboratory production. Governments should make a political decision in this regard in the interest of equity in population health. In the Region of the Americas, these actions could be part of a program led by the Pan American Health Organization to ensure the availability of these biologicals in strategically located health centers. Twelve public facilities producing antivenoms have been identified in the Region, including Brazil and Mexico, which are the biggest public producers. These laboratories should be managed like industrial operations that produce tangible goods without ignoring strategic planning. National regulatory authorities should help the public laboratories that produce them by providing necessary technical assistance and consultancy without any loss of impartiality or rigor in the evaluation of their quality management systems. New superior production technologies using hyperimmune mammalian plasma are in the experimental phase; no information on its production has been found in the literature. |
format | Online Article Text |
id | pubmed-6645312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Organización Panamericana de la Salud |
record_format | MEDLINE/PubMed |
spelling | pubmed-66453122019-08-05 La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad Temprano, Guillermo Aprea, Patricia Christian Dokmetjian, José Rev Panam Salud Publica Opinión Y Análisis Injuries caused by venomous animals affect vast areas of Latin America, Southern Asia, Southeast Asia, sub-Saharan Africa, and Oceania, and pose a serious problem for global public health. Based on an analysis of the current panorama of global production of ophidian and arachnid antivenoms, it is concluded that they are semi-orphaned products. This is a favorable scenario in which to strengthen public laboratory production. Governments should make a political decision in this regard in the interest of equity in population health. In the Region of the Americas, these actions could be part of a program led by the Pan American Health Organization to ensure the availability of these biologicals in strategically located health centers. Twelve public facilities producing antivenoms have been identified in the Region, including Brazil and Mexico, which are the biggest public producers. These laboratories should be managed like industrial operations that produce tangible goods without ignoring strategic planning. National regulatory authorities should help the public laboratories that produce them by providing necessary technical assistance and consultancy without any loss of impartiality or rigor in the evaluation of their quality management systems. New superior production technologies using hyperimmune mammalian plasma are in the experimental phase; no information on its production has been found in the literature. Organización Panamericana de la Salud 2017-07-20 /pmc/articles/PMC6645312/ /pubmed/28902267 http://dx.doi.org/10.26633/RPSP.2017.109 Text en https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Opinión Y Análisis Temprano, Guillermo Aprea, Patricia Christian Dokmetjian, José La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad |
title | La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad |
title_full | La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad |
title_fullStr | La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad |
title_full_unstemmed | La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad |
title_short | La producción pública de antivenenos en la Región de las Américas como factor clave en su accesibilidad |
title_sort | la producción pública de antivenenos en la región de las américas como factor clave en su accesibilidad |
topic | Opinión Y Análisis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645312/ https://www.ncbi.nlm.nih.gov/pubmed/28902267 http://dx.doi.org/10.26633/RPSP.2017.109 |
work_keys_str_mv | AT tempranoguillermo laproduccionpublicadeantivenenosenlaregiondelasamericascomofactorclaveensuaccesibilidad AT apreapatricia laproduccionpublicadeantivenenosenlaregiondelasamericascomofactorclaveensuaccesibilidad AT christiandokmetjianjose laproduccionpublicadeantivenenosenlaregiondelasamericascomofactorclaveensuaccesibilidad |